Blood cancers

Hypertension risk noted (again) with ibrutinib

There’s more evidence of the cardiotoxicity of ibrutinib with a US study finding new or worsened hypertension in 78.3% of patients with B-cell malignancies started on the Bruton’s tyrosine kinase inhibitor. Using a hypertension definition of systolic blood pressure ≥130 mmHg, the study of 562 adults with a range of malignancies, but mostly CLL, found ...

Already a member?

Login to keep reading.

© 2021 the limbic